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Abstract
Background The TRITON-TIMI 38 study has identified
three subgroups of patients with a higher risk of bleeding
during treatment with the thienopyridine prasugrel: patients
with a history of stroke or transient ischaemic attack (TIA),
patients ≥75 years and patients with a body weight <60 kg.
However, the underlying pathobiology leading to this
increased bleeding risk remains to be elucidated. The
higher bleeding rate may be due to a stronger prasugrel-
induced inhibition of platelet aggregation in these sub-
groups. The aim of the present study was to determine
whether on-treatment platelet reactivity is lower in these
risk subgroups as compared with other patients in a large
cohort on the thienopyridine clopidogrel undergoing elec-
tive coronary stenting.
Methods A total of 1069 consecutive patients were en-
rolled. On-clopidogrel platelet reactivity was measured in
parallel by light transmittance aggregometry, the Verify-
Now® P2Y12 assay and the PFA-100 collagen/ADP
cartridge.
Results Fourteen patients (1.5%) had a prior history of
stroke or TIA, 138 patients (14.5%) were older than
75 years and 30 patients (3.2%) had a body weight
<60 kg. Age ≥75 years and a history of stroke were
independent predictors of a higher on-treatment platelet
reactivity. In contrast, a body weight <60 kg was
significantly associated with a lower on-treatment platelet
reactivity.
Conclusion In two high-risk subgroups for bleeding,
patients ≥75 years and patients with previous stroke, on-
clopidogrel platelet reactivity is increased. In contrast, in
patients with a low body weight, on-clopidogrel platelet
reactivity is decreased, suggesting that a stronger response
to a thienopyridine might only lead to more bleeds in
patients with low body weight
Keywords Clopidogrel . Platelet reactivity
Introduction
Dual antiplatelet therapy with aspirin and the thienopyr-
idine clopidogrel is the therapy of choice in patients
undergoing percutaneous coronary intervention (PCI) with
stent implantation [1, 2]. However, despite this treatment
ischaemic events still occur, and multiple studies have
clearly demonstrated a relationship between the magnitude
of on-treatment platelet reactivity and the occurrence of
atherothrombotic events [3–8]. Therefore, novel antiplatelet
agents with more consistent response rates among patients
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have been introduced. One of these is the thienopyridine
prasugrel which, similar to clopidogrel, is a specific,
irreversible adenosine diphosphate (ADP)-receptor antago-
nist, but it is faster acting and a more potent platelet
inhibitor. The Trial to Assess Improvement in Therapeutic
Outcomes by Optimising Platelet Inhibition with Prasugrel–
Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI
38) demonstrated a significant risk reduction for the
occurrence of thrombotic events in patients with an acute
coronary syndrome (ACS) undergoing PCI with prasugrel
as compared with clopidogrel [9]. This reduction, however,
was counterbalanced by a 30% increased risk of bleeding,
suggesting a link between platelet reactivity inhibition and
bleeding [10, 11].
Three subgroups of patients were identified as having
less clinical efficacy from prasugrel and greater absolute
risk of bleeding than the overall cohort. These included (1)
patients with a prior history of stroke or transient ischaemic
attack (TIA), (2) the elderly (≥75 years of age), and (3)
patients with a body weight <60 kg [9]. However, the
underlying pathobiology leading to this increased bleeding
risk remains to be elucidated.
It has been hypothesised that the higher bleeding rate may
be due to a stronger prasugrel-induced inhibition of ADP-
induced platelet aggregation in these subgroups. Since
prasugrel has been introduced only recently, few pharmaco-
dynamic data are available. However, in the POPular study
(The Do Platelet Function Assays Predict Clinical Outcomes
in Clopidogrel Pretreated Patients Undergoing Elective PCI
study), the influence of the other thienopyridine clopidogrel
on the inhibition of platelet reactivity was determined in
patients undergoing elective coronary stent implantation. The
aim of the present sub-analysis study was to establish whether
the on-clopidogrel platelet reactivity is lower in the three
subpopulations at risk for bleeding as compared with in other
patients in a large cohort of patients on clopidogrel undergo-
ing elective coronary stenting.
Methods
Study population
The POPular study was a prospective, observational study
that included consecutive patients with established coronary
artery disease scheduled for elective PCI with stent
implantation. The entry and exclusion criteria were de-
scribed in the original publication [3]. All patients had been
on dual antiplatelet therapy with clopidogrel and low-dose
aspirin of 80–100 mg daily for at least 10 days, unless they
were on long-term treatment with coumarin derivates. This
study complied with the Declaration of Helsinki and was
approved by the local institutional review board. Written
informed consent was obtained from every patient prior to
elective PCI.
Blood sampling and platelet function testing
Prior to heparinisation, whole blood was drawn from the
femoral or radial artery sheath. After discarding the first
10 ml of blood, samples were collected into citrated tubes
(3.2% for light transmittance aggregometry (LTA) and the
VerifyNow® system and 3.8% for PFA). The magnitude of
platelet reactivity was measured using three platelet
function tests in parallel; the platelet function analyser
(PFA-100) and ‘classical’ LTA. All methods were per-
formed between 30 min and 2 h after blood collection.
Light transmittance aggregometry
LTAwas quantified in non-adjusted platelet-rich plasma on
a four-channel APACT 4004 aggregometer (LABiTec,
Arensburg, Germany). Platelet-poor plasma was set as
100% aggregation, and maximal (peak) platelet aggregation
(%) was measured spontaneously and after stimulation by
ADP in final concentrations of 5 and 20 μmol/L.
The VerifyNow® P2Y12 assay
The VerifyNow® P2Y12 assay (Accumetrics, Inc, San
Diego, USA) is an automated whole blood, cartridge-
based method to determine the magnitude of platelet
agglutination as induced by ADP/prostaglandin E1 [12].
The results are reported in P2Y12 Reaction Units.
PFA-100
The PFA-100 System (Siemens Healthcare Diagnostics
Products GmbH, Germany) measures platelet function, in
particular adhesion and aggregation, in whole blood under
high shear conditions (5000 s−1) [13]. The time needed to
form a platelet plug occluding the aperture cut into a
membrane coated with collagen/ADP, an agonist, was
determined and reported as closure time in seconds, which
is inversely related to platelet reactivity. A closure time of
>300 s was referred to as ‘non-closure’.
Statistical analysis
Continuous variables are presented as mean (SD). Categorical
data are reported as frequencies (percentages). Categorical
variables were compared using the χ2 test or Fisher’s exact
test when frequencies were <5. The distribution of variables
was determined by the Kolmogorov–Smirnov goodness-of-
fit test. Normally distributed continuous variables were
compared with a two-sided unpaired t test.
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Logistic regression modelling was performed to identify
independent correlates of the magnitude of platelet reactiv-
ity and to adjust for potential confounders. Being part of a
high-risk group was entered as a dichotomous variable. All
univariate variables with a p value <0.10 were included in
multivariable analysis (binary logistic regression).
Results
Patient characteristics
A total of 1069 consecutive patients were enrolled, of
whom 951 were on aspirin >10 days. The latter comprised
the present study population. Owing to irregularities in
platelet assay supply, as well as technical failure in a
minority of platelet function tests, not all platelet function
assays were performed in every patient.
Baseline characteristics of the total population are depicted
in Table 1. Fourteen patients (1.5%) had a history of stroke
or TIA, 138 patients (14.5%) were older than 75 years of age
and 30 patients (3.2%) had a body weight <60 kg. Patients
≥75 years were more often female and smoker and had a
lower haemoglobin. They were less often treated with statins
and the proportion of hypercholesterolaemia, renal failure
and an impaired ejection fraction was higher. Patients with a
history of stroke or TIA more frequently received a loading
dose of clopidogrel and more often had a previous history of
coronary artery bypass grafting. Patient with a body weight
<60 kg were significantly older, had lower haemoglobin and
were less often treated with statins and β-blockade. The
proportion of females was higher in this group, the frequency
of diabetes mellitus and hypertension was lower and the
minimal stent diameter was smaller.
Old age as risk factor for low platelet reactivity
Elderly patients ≥75 years had a significantly higher
magnitude of on-treatment platelet reactivity as compared
with patients <75 years, regardless of the platelet function
test used. (Fig. 1a; Table 2) After adjustment for factors
known to influence platelet function (diabetes mellitus,
smoking, gender, concomitant use of proton pump inhibitors
and the administration of a loading dose of clopidogrel), an
age ≥75 years remained an independent predictor of a higher
magnitude of platelet reactivity, except when 20 μmol/L-
induced LTAwas used (Table 2).
Cerebrovascular accident as risk factor for low platelet
reactivity
In patients with a history of stroke or TIA, the magnitude of
platelet reactivity was significantly higher as compared
with patients without a previous cerebrovascular accident
when platelet reactivity was established using LTA (both 5
and 20 μmol/L ADP-induced aggregation) (Fig. 1b; Ta-
ble 2). After adjustment for potential confounders, a history
of stroke or TIA remained an independent predictor of a
higher level of aggregation. In contrast, no significant
difference was found between the group with and without a
history of stroke or TIA when platelet reactivity was
assessed using the VerifyNow® P2Y12 assay or the PFA
COL/ADP cartridge (Table 2).
Table 1 Baseline characteristics
Total population
Clinical parameters
Age (years) 64±10.6
BMI (kg/m2) 27.3±3.9
Gender (male) 717/951 (75.4%)
Hypertension 737/951 (77.5%)
Hypercholesterolaemia 769/951 (80.9%)
Diabetes mellitus 175/951 (18.4%)
Family history 580/951 (61.0%)
Current smoking 107/951 (11.3%)
Impaired ejection fraction 133/951 (14.0%)
Renal insufficiency 72/951 (7.6%)
Prior myocardial infarction 519/951 (54.6%)
Prior PCI 304/951 (32.0%)
Prior CABG 93/951 (9.8%)
Medication
Loading dose clopidogrel 489/951 (51.4%)
Statin 767/951 (80.7%)
β-blocker 733/951 (77.1%)
ACE inhibitor 345/951 (36.3%)
Proton pump inhibitor 270/951 (28.4%)
Calcium channel blocker 365/951 (38.4%)
Oral anti-diabetic agents 62/951 (6.5%)
Coumarin derivatives 24/951 (2.5%)
Laboratory parameters
Platelet count (×109) 273.4±78.8
White blood cell count (×109) 7.7±2.3
Haemoglobin (mmol/L) 8.6±2.2
Procedural parameters
No. of stents implanted 1489/950 1.57
No. of lesions treated 1317/951 1.38
Minimal stent diameter (mm) 3.1±0.8
Total stent length (mm) 28.3±17.1
Bifurcation lesion 32/951 (3.4%)
Drug-eluting stent 604/946 (63.8%)
Left anterior descending artery 450/951 (47.3%)
Graft 28/951 (2.9%)
ACE angiotensin-converting enzyme, BMI body mass index, CABG
coronary artery bypass grafting
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Low body weight as risk factor for low platelet reactivity
Aggregation as measured by 20 μmol/L ADP-induced
LTA was significantly lower in patients with a body
weight <60 kg as compared with patients with a higher
body weight. None of the other tests identified signifi-
cant differences between patients with a low body weight
and patients with a body weight >60 kg (Fig. 1c,
Table 2). After adjustment for potential confounding
factors, lower body weight remained significantly associ-
ated with an intensified platelet response to clopidogrel as
established by either 20 μmol/L ADP-induced LTA and
became significant when measured with the VerifyNow®
P2Y12 assay (Table 2).
Discussion
Whereas TRITON-TIMI 38 demonstrated that prasugrel, a
thienopyridine resulting in lower on-treatment platelet
reactivity as compared with clopidogrel, was associated
with less recurrent atherothrombotic events in ACS patients
undergoing PCI, an increased risk of bleeding was observed
in patients treated with prasugrel [9]. The presence of a
therapeutic window was already acknowledged by Para-
celsus, who stated as early as in the fifteenth century that
‘All drugs are poisons, the benefit depends on the dosage’
[14]. There is currently a growing body of evidence
supporting the association between bleeding and adverse
outcomes, including myocardial infarction, stroke and death
Fig. 1 Magnitude of platelet reactivity. Magnitude of platelet
reactivity according to the three tests used. Since the PFA-100®
System confines detection of a closure time to a 300-s window, the
results of the PFA-100® System are depicted as a cumulative Kaplan–
Meier time-to-aperture-closure plot and a log-rank test was used. a In
patients <75 years vs. patients ≥75 years of age. b In patients with a
history of TIA or stroke vs. patients without a history of TIA or stroke.
c In patients <60 kg vs. patients ≥60 kg
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[15–17], and several studies have suggested a link between
the inhibition of platelet reactivity and the occurrence of
bleeding [10, 18–20]. Thus, the identification of a window
of platelet inhibition that on the one hand prevents
atherothrombotic events and on the other hand does not
lead to an increase in bleeding events, is of utmost
importance [21].
The TRITON-TIMI 38 study has identified three
subgroups of patients with a higher risk of bleeding during
treatment with prasugrel: (1) patients with a prior history of
stroke or TIA, (2) the elderly (>75 years of age), and (3)
patients with a body weight less <60 kg [9]. However, the
underlying pathobiology leading to this increased bleeding
risk remains to be elucidated. It has been hypothesised that
the higher bleeding rate might be the consequence of a
stronger prasugrel-induced inhibition of ADP-induced
platelet aggregation in these subgroups. Since prasugrel
was introduced only recently, few pharmacodynamic data
are available. The present study, with the aim to determine
whether on-clopidogrel platelet reactivity is lower in these
risk subgroups as compared with other patients, demon-
strated that in the two high-risk subgroups for bleeding,
patients >75 years of age and patients with previous stroke,
on-treatment platelet reactivity is contrarily increased.
However, in the third high-risk subgroup for bleeding,
patients with a low body weight, on-treatment platelet
reactivity is indeed decreased. When these data are applied
to the hypothesis that prasugrel leads to a stronger platelet
inhibition, it seems that in TRITON-TIMI 38, a stronger
response to prasugrel might have only led to more bleeds in
patients with low body weight.
These observations are in line with results from a recent
analysis of 16 phase-I clinical pharmacological studies
performed in healthy patients. In this analysis, no effect of
advanced age on the availability of the active metabolite of
prasugrel was perceived [22]. On the contrary, in the
TRITON-TIMI 38, patients ≥75 years had 19% higher
exposure to the active metabolite as compared with those
<75 years and even 25% higher exposure as compared with
patients <60 years of age [23]. However, in the latter the
concentration of the active metabolite was not measured,
but estimated from its inactive metabolite. In contrast, body
weight had the greatest influence on exposure to the active
metabolite of prasugrel in both clinical pharmacology
studies and the TRITON-TIMI 38, with an increase in
exposure as body weight decreased. Exposure was 40%
higher in individuals <60 kg as compared with those
≥60 kg [22, 23]. Modelling data suggest that decreasing the
maintenance dose of prasugrel to 5 mg in these subjects
would reduce exposure to the active metabolite to levels
Table 2 Magnitude of platelet reactivity
Magnitude of platelet reactivity in the elderly
<75 year (n=815) ≥75 year (n=136) p value After adjustment
Difference p value
LTA 20 ADP 57.2±14.5 59.7±13.8 0.047 2.10 0.11
LTA 5 ADP 39.3±14.5 43.1±14.4 0.0046 3.3 0.01
PRU 202.9±74.9 233.5±75.2 <0.0001 25.9 0.0001
PFA COL/ADP NA NA 0.008 NA 0.008
Magnitude of platelet reactivity in patients with a history of a cerebrovascular event
No TIA/stroke (n=937) Previous TIA/stroke (n=14) p value After adjustment
Difference p value
LTA 20 ADP 57.4±14.4 67.0±11.3 0.007 8.46 0.03
LTA 5 ADP 39.7±14. 6 48.8±10. 6 0.007 8.46 0.03
PRU 206.8±75.6 245.5±71. 5 0.07 37.4 0.06
PFA COL/ADP NA NA 0.09 NA 0.11
Magnitude of platelet reactivity in patients with a low body weight
≥60 kg (n=921) <60 kg (n=30) p value After adjustment
Difference p value
LTA 20 ADP 57.7±14.3 51.6±15.8 0.046 −7.2 0.007
LTA 5 ADP 39.9±14.5 37.7±15.4 0.45 −3.9 0.16
PRU 207.7±75.1 198.7±91.4 0.61 −28.1 0.04
PFA COL/ADP NA NA 0.87 NA 0.76
LTA light transmittance aggregometry, NA not applicable, PRU P2Y12 reaction units, PFA COL/ADP platelet function analyser using the collagen/
ADP cartridge
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consistent with those <75 years and ≥60 kg [22]. Both
European and American regulatory agents therefore recom-
mend a daily dose of 5 mg in patients <60 kg. For patients
≥75 years, the US Food and Drug Administration advises
that prasugrel is generally not recommended, but might be
considered in patients at high risk of recurrent atherothrom-
botic events at a maintenance dose of 10 mg in those ≥60 kg
[23]. On the contrary, the European Medicines Agency
recommends that prasugrel is avoided in the elderly, but if
used, the dose should be halved to 5 mg [23]. Taking the
findings from the present study into account and the fact that
elderly patients have a higher risk of bleeding as compared
with younger individuals, even when not on thienopyridine
therapy [24], we do not consider prasugrel to result in an
excess in platelet inhibition, thereby accounting for the
increased bleeding risk in this population.
In conclusion, the results from the present analysis
confirmed previous studies and identified body weight as
the most influential covariate on the magnitude of ADP-
induced platelet reactivity, which might have implications
for prasugrel maintenance dose in daily clinical practice.
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